Diltiazem Hydrochloride

證據等級: L5

預測適應症: 0 個

---

目錄

1. Diltiazem Hydrochloride
2. Diltiazem Hydrochloride: Drug Repurposing Evaluation — Critical Data Gaps Identified
   1. One-Sentence Summary
   2. Quick Overview
   3. South Africa Market Information
   4. Safety Considerations
   5. Conclusion and Next Steps
   6. Disclaimer

---

## 藥師評估報告

Diltiazem Hydrochloride: Drug Repurposing Evaluation — Critical Data Gaps Identified

One-Sentence Summary

Diltiazem Hydrochloride is an established cardiovascular agent; however, this Evidence Pack contains no mechanism of action data, no SAHPRA registration records, and — critically — no TxGNN-predicted repurposing indications. Without these foundational inputs, no repurposing direction can be assessed at this stage. This report documents the current data status and outlines the steps required before a full evaluation can proceed.

---

Quick Overview

Item	Content
Original Indication	No registration data available
Predicted New Indication	No predictions generated
TxGNN Prediction Score	Not available
Evidence Level	Not applicable — no predictions exist
South Africa Market Status	Not Registered
Number of SAHPRA Registrations	0
Recommended Decision	Hold

---

South Africa Market Information

Diltiazem Hydrochloride currently has no active SAHPRA registrations in South Africa.

Practical implications for healthcare professionals:

• The product is not available through the formal medicines regulatory pathway.
• Any clinical or research use would require a Section 21 authorisation (unregistered medicine application) from SAHPRA before the product may be supplied or used.
• Prescribers and pharmacists should consult SAHPRA’s online portal to confirm current registration status before sourcing this product.

---

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Diltiazem Hydrochloride is incomplete in several critical areas: the TxGNN pipeline produced no repurposing predictions, no SAHPRA registrations exist, the mechanism of action is unresolved, and no safety profile (warnings or contraindications) has been retrieved. A repurposing evaluation cannot be meaningfully conducted in the absence of these inputs.

To proceed, the following is needed:

1. Resolve Blocking Data Gap (DG001) — Prescribing Information: Obtain the full PI/package insert (including key warnings and contraindications) from the originator’s regulatory dossier or an equivalent approved national medicine authority (e.g., EMA, FDA, or TGA-sourced PI as a reference document). This is a blocking prerequisite for safety screening.

2. Resolve High-Priority Data Gap (DG002) — Mechanism of Action: Retrieve MOA data via the DrugBank API. A query was logged as successful (query log ID 1, result count: 1) but no DrugBank ID was returned — re-run the lookup to capture the correct DrugBank entry and full pharmacological profile.

3. Re-run TxGNN Prediction Pipeline: Once Diltiazem Hydrochloride is correctly mapped to a DrugBank ID, re-run both the knowledge graph (KG) and deep-learning (DL) prediction models to generate repurposing candidates with scored indications.

4. SAHPRA Registration Pathway: If a repurposing indication is confirmed with sufficient evidence, initiate the appropriate SAHPRA pathway — either a new registration application or a Section 21 unregistered medicine authorisation — depending on the urgency and clinical context.

   Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---